Therapeutic effects of 1,25-dihydroxyvitamin D3 on diabetes-induced liver complications in a rat model

Liu,Lina; Lv,Guodong; Ning,Conghua; Yang,Ye; Zhu,Jun

doi:10.3892/etm.2016.3242

Therapeutic effects of 1,25-dihydroxyvitamin D3 on diabetes-induced liver complications in a rat model

Authors:
- Lina Liu
- Guodong Lv
- Conghua Ning
- Ye Yang
- Jun Zhu
View Affiliations

Affiliations: Department of Endocrinology, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China, Institute of Research, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830054, P.R. China
Published online on: April 11, 2016 https://doi.org/10.3892/etm.2016.3242
Pages: 2284-2292
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been suggested that 1,25-dihydroxyvitamin D3 (vitamin D) plays a protective role against inflammation and insulin resistance (IR) in type 2 diabetes mellitus (T2DM). The present study investigate the hypothesis that vitamin D may exert beneficial effects on the liver in a rat model of T2DM by regulating the expression of inflammation‑related cytokines and ameliorating IR induced by inflammation. Normal control group rats were fed a basic diet (NC). Experimental rats received a high‑fat diet for 8 weeks and were then injected with streptozotocin (STZ) to induce T2DM. Half of the T2DM model rats received vitamin D (0.03 µg/kg/day) for 8 weeks (vitamin D‑treated group; VD; n=11), while the other (T2DM group; DM; n=10) and NC group received an equivalent quantity of peanut oil. Following sacrifice, fasting plasma glucose (FPG) and fasting insulin (FINS) were recorded and homeostasis model assessment of IR (HOMA‑IR) was calculated. Liver histopathology was examined using hematoxylin and eosin staining. The levels of the inflammatory cytokines C‑Jun N‑terminal kinase, C‑Jun, tumor necrosis factor‑α and interleukin‑1β were measured using immunohistology, quantitative polymerase chain reaction and western blot analyses. The results revealed that treatment with vitamin D markedly alleviated the pathological alterations of liver and reduced the expression of inflammatory cytokines at the protein and mRNA levels. Furthermore, decreased levels of FPG, HOMA‑IR and increased FINS were detected. In conclusion, the results of the present study indicate that vitamin D has therapeutic effects on diabetes-induced liver complications in T2DM model rats, which may involve the modulation of the inflammatory response, attenuating the 'crosstalkʼ between inflammation and IR and ameliorating hyperglycemic state.

View Figures

View References

1	Guadarrama-López AL, Valdés-Ramos R and Martínez-Carrillo BE: Type 2 diabetes, PUFAs, and vitamin D: Their relation to inflammation. J Immunol Res. 2014:8607032014. View Article : Google Scholar : PubMed/NCBI
2	Flores M: A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev. 18:175–182. 2005. View Article : Google Scholar : PubMed/NCBI
3	Chiu KC, Chu A, Go VL and Saad MF: Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 79:820–825. 2004.PubMed/NCBI
4	Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE and Hu FB: Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 29:650–656. 2006. View Article : Google Scholar : PubMed/NCBI
5	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
6	Gregor MF and Hotamisligil GS: Inflammatory mechanisms in obesity. Ann Rev Immunol. 29:415–445. 2011. View Article : Google Scholar
7	Sattar N, McCarey DW, Capell H and McInnes IB: ‘Explaining how high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 108:2957–2963. 2003. View Article : Google Scholar : PubMed/NCBI
8	Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y and Schattner A: Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 98:2751–2756. 2003. View Article : Google Scholar : PubMed/NCBI
9	Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R and Mathieu C: Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract. 77:47–57. 2007. View Article : Google Scholar : PubMed/NCBI
10	Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G and Arcaro G: Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 17:517–524. 2007. View Article : Google Scholar : PubMed/NCBI
11	Laskin DL, Weinberger B and Laskin JD: Functional heterogeneity in liver and lung macrophages. J Leukoc Biol. 70:163–170. 2001.PubMed/NCBI
12	Korf H, Wenes M, Stijlemans B, Takiishi T, Robert S, Miani M, Eizirik DL, Gysemans C and Mathieu C: 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology. 217:1292–1300. 2012. View Article : Google Scholar : PubMed/NCBI
13	Alroy I, Towers TL and Freedman LP: Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 15:5789–5799. 1995. View Article : Google Scholar : PubMed/NCBI
14	Ip YT and Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol. 10:205–219. 1998. View Article : Google Scholar : PubMed/NCBI
15	Karin M and Gallagher E: From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life. 57:283–295. 2005. View Article : Google Scholar : PubMed/NCBI
16	Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, Kajimoto Y, Matsuhisa M, Yamasaki Y and Hori M: Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem. 279:45803–45809. 2004. View Article : Google Scholar : PubMed/NCBI
17	Yang R and Trevillyan JM: c-Jun N-terminal kinase pathways in diabetes. Int J Biochem Cell Biol. 40:2702–2706. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sharfi H and Eldar-Finkelman H: Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab. 294:E307–E315. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kaneto H: The JNK pathway as a therapeutic target for diabetes. Expert Opin Ther Targets. 9:581–592. 2005. View Article : Google Scholar : PubMed/NCBI
20	Tarantino G and Caputi A: JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J Gastroenterol. 17:3785–3794. 2011. View Article : Google Scholar : PubMed/NCBI
21	Chagas CE, Borges MC, Martini LA and Rogero MM: Focus on vitamin D, inflammation and type 2 diabetes. Nutrients. 4:52–67. 2012. View Article : Google Scholar : PubMed/NCBI
22	Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M and Hotamisligil GS: Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci USA. 103:10741–10746. 2006. View Article : Google Scholar : PubMed/NCBI
23	Micheau O and Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 114:181–190. 2003. View Article : Google Scholar : PubMed/NCBI
24	Seki E, Brenner DA and Karin M: A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI
25	Schwabe RF, Uchinami H, Qian T, Bennett BL, Lemasters JJ and Brenner DA: Differential requirement for c-Jun NH2-terminal kinase in TNF alpha-and Fas-mediated apoptosis in hepatocytes. FASEB J. 18:720–722. 2004.PubMed/NCBI
26	Li H, Xie H, Fu M, Li W, Guo B, Ding Y and Wang Q: 25-hydroxyvitamin D3 ameliorates periodontitis by modulating the expression of inflammation-associated factors in diabetic mice. Steroids. 78:115–120. 2013. View Article : Google Scholar : PubMed/NCBI
27	Hotamisligil GS, Shargill NS and Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science. 259:87–91. 1993. View Article : Google Scholar : PubMed/NCBI
28	Bieghs V and Trautwein C: The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 34:446–452. 2013. View Article : Google Scholar : PubMed/NCBI
29	Negrin KA, Roth Flach RJ, Di Stefano MT, Matevossian A, Friedline RH, Jung D, Kim JK and Czech MP: IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PloS One. 9:e1072652014. View Article : Google Scholar : PubMed/NCBI
30	Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T and Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 356:1517–1526. 2007. View Article : Google Scholar : PubMed/NCBI
31	Moore M, Piazza A, Nolan Y and Lynch MA: Treatment with dexamethasone and vitamin D3 attenuates neuroinflammatory age-related changes in rat hippocampus. Synapse. 61:851–861. 2007. View Article : Google Scholar : PubMed/NCBI
32	Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH and Hotamisligil GS: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 306:457–461. 2004. View Article : Google Scholar : PubMed/NCBI
33	Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW and Olefsky JM: JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem. 280:35361–35371. 2005. View Article : Google Scholar : PubMed/NCBI
34	Meeker S, Seamons A, Paik J, Treuting PM, Brabb T, Grady WM and Maggio-Price L: Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res. 74:4398–4408. 2014. View Article : Google Scholar : PubMed/NCBI
35	Zhou QG, Hou FF, Guo ZJ, Liang M, Wang GB and Zhang X: 1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab Res Rev. 24:459–464. 2008. View Article : Google Scholar : PubMed/NCBI
36	Scragg R, Sowers M and Bell C: Third National Health and Nutrition Examination Survey: Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care. 27:2813–2818. 2004. View Article : Google Scholar : PubMed/NCBI
37	von Hurst PR, Stonehouse W and Coad J: Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br J Nutr. 103:549–555. 2010. View Article : Google Scholar : PubMed/NCBI
38	Hotamisligil GS: Inflammation and metabolic disorders. Nature. 444:860–867. 2006. View Article : Google Scholar : PubMed/NCBI
39	Nugent DA, Smith DM and Jones HB: A review of islet of Langerhans degeneration in rodent models of type 2 diabetes. Toxicol Pathol. 36:529–551. 2008. View Article : Google Scholar : PubMed/NCBI
40	Meerza D, Naseem I and Ahmed J: Effect of 1,25(OH)₂ vitamin D₃ on glucose homeostasis and DNA damage in type 2 diabetic mice. J Diabetes Complications. 26:363–368. 2012. View Article : Google Scholar : PubMed/NCBI